Disease/Infection News

RSS

A Selection of Today's Opinions: AIDS endures; Conservatives' changing views of the individual mandate; Concerns for doctors

AIDS endures right here in the U.S.A.: our outpatient clinics are bursting at the seams, and new cases show up daily. A million domestic stories are languishing untold, but they are not the operatic tragedies we have grown used to (Dr. Abigail Zuger, 4/19).

21 Apr 2010

AMRI extends and expands research collaboration with CHDI Foundation

AMRI announced today the five year extension and expansion of its ongoing research collaboration with CHDI Foundation, Inc. (CHDI), focused on the discovery of new therapeutic agents for the treatment of Huntington's disease (HD).

20 Apr 2010

Cal/OSHA issues $101,485 in citations to Alta Bates Summit Medical Center in Oakland

The Department of Industrial Relations' Division of Occupational Safety and Health, better known as Cal/OSHA, today issued $101,485 in citations to Alta Bates Summit Medical Center in Oakland for ten violations of the state safety and health standards in connection to a life-threatening exposure of bacterial meningitis.

20 Apr 2010

Ovale malaria is two similar but distinct species that do not reproduce with each other: Research

Scientists investigating ovale malaria, a form of the disease thought to be caused by a single species of parasite, have confirmed that the parasite is actually two similar but distinct species which do not reproduce with each other, according to research published in The Journal of Infectious Diseases.

20 Apr 2010

Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis

QLT Inc. today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.

20 Apr 2010

Prevalence of scalp fungus infection among children living in metropolitan areas

Approximately 7 percent of elementary school children across the bi-state, Kansas City metropolitan area are infected with the fungus Trichophyton tonsurans (T. tonsurans), the leading cause of ringworm in the U.S., according to a new study published today in Pediatrics. This is the largest study to date aimed at defining infection prevalence of the scalp fungus in children living in a metropolitan area and has implications for children nationwide.

20 Apr 2010

NanoBio to develop intranasal vaccine for HBV

NanoBio® Corporation today announced an initiative to develop an intranasal vaccine for the treatment of hepatitis B (HBV). NanoBio and the University of Michigan's, Michigan Nanotechnology Institute for Medicine and Biological Sciences received funding through a Phase 1 Technology Transfer (STTR) award by the National Institutes of Health (NIH), to evaluate a potential therapeutic intranasal vaccine for the treatment of hepatitis B in patients.

20 Apr 2010

Lactobacillus plantarum has no effect on Salmonella: University of Gothenburg

Many tourists travelling abroad go down with diarrhoea, which can be caused by Salmonella. While probiotics are often cited as the solution to various stomach problems, the probiotic, Lactobacillus plantarum has no effect on Salmonella, reveals a new thesis at the University of Gothenburg, Sweden.

20 Apr 2010

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

Though the world has made "great strides" in eliminating H5N1 (avian flu) from poultry since the "peak of its outbreak in 2006" in 63 countries, the virus persists in Bangladesh, China, Egypt, Indonesia and Vietnam, VOA News reports (DeCapua, 4/16).

20 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

Opinions: PEPFAR; Private-civil society partnerships in Africa; Global maternal mortality; SA HIV testing campaign

"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.

20 Apr 2010

New research shows link between infection-related diseases and risk of cancer

New research is emerging that suggests a link between infection-related diseases and risk of cancer, according to findings presented here at the American Association for Cancer Research 101st Annual Meeting 2010.

20 Apr 2010

Gilead Sciences halts Phase II trial of GS 9450 for chronic hepatitis C

Gilead Sciences, Inc. today announced the company is stopping its ongoing Phase II clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C. This decision follows reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.

20 Apr 2010

Novartis withdraws EMA MAA for JOULFERON

Human Genome Sciences, Inc. today announced that Novartis has withdrawn a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN™) for the treatment of chronic hepatitis C.

19 Apr 2010

BioMarin Pharmaceutical introduces Firdapse for LEMS in the E.U.

BioMarin Pharmaceutical Inc. announced today that Firdapse™ (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Launching immediately in Germany and the UK, the company expects to subsequently launch Firdapse in all major European markets by the end of 2010.

19 Apr 2010

Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Didanosine Delayed-release Capsules, 125 mg, 200 mg, 250 mg and 400 mg, the generic version of Bristol Myers Squibb's HIV treatment Videx® EC.

19 Apr 2010

Resistance to antibiotics on the increase in intestinal bacteria in animals: Study

Anne-Mette R. Grønvold has through her doctoral research shown that resistance to antibiotics is on the increase in intestinal bacteria in animals as a direct result of antibiotic treatments. The antibiotics also alter the composition of bacteria in the intestines.

19 Apr 2010

Researchers reveal new switch to Salmonella bacteria: Science

A new switch that enables Salmonella bacteria to sabotage host cells is revealed in a study published today in the journal Science.

19 Apr 2010

New in vitro study results of Hydrofiber dressing to be presented at SAWC/WHS 2010

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results in which a Hydrofiber dressing containing ionic silver was observed to conform more closely to a porcine tissue surface in a shallow wound model than did certain silver-containing foam dressings following hydration.

19 Apr 2010

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Protein Potential LLC has received support from the National Institute of Allergy and Infectious Diseases of the NIH in the form of a Phase II Small Business Innovation Research Grant. The three-year award totaling approximately $3 million will support translational research to develop a vaccine for the prevention of malaria caused by the parasite Plasmodium vivax.

19 Apr 2010

Disease/Infection News

A Selection of Today's Opinions: AIDS endures; Conservatives' changing views of the individual mandate; Concerns for doctors

AMRI extends and expands research collaboration with CHDI Foundation

Cal/OSHA issues $101,485 in citations to Alta Bates Summit Medical Center in Oakland

Ovale malaria is two similar but distinct species that do not reproduce with each other: Research

Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis

Prevalence of scalp fungus infection among children living in metropolitan areas

NanoBio to develop intranasal vaccine for HBV

Lactobacillus plantarum has no effect on Salmonella: University of Gothenburg

Avian flu's endurance in 5 countries poses global threat to human health, FAO official says

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

Opinions: PEPFAR; Private-civil society partnerships in Africa; Global maternal mortality; SA HIV testing campaign

New research shows link between infection-related diseases and risk of cancer

Gilead Sciences halts Phase II trial of GS 9450 for chronic hepatitis C

Novartis withdraws EMA MAA for JOULFERON

BioMarin Pharmaceutical introduces Firdapse for LEMS in the E.U.

Matrix Laboratories' ANDA for Didanosine Delayed-release Capsules receives FDA approval under PEPFAR

Resistance to antibiotics on the increase in intestinal bacteria in animals: Study

Researchers reveal new switch to Salmonella bacteria: Science

New in vitro study results of Hydrofiber dressing to be presented at SAWC/WHS 2010

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Latest News